Tygacil 50Mg Iv Injection

Brand : pfizer laboratories

Rs. 2,261.00

Rs. 2,380.00

|

QUICK DELIVERY

SPECIFICATION

Requires Prescription (YES/NO)

Yes

Generics

Tigecycline

Used For

Bacterial Infection

How it works

Tigecycline inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains.

USAGE AND SAFETY

Dosage

Tigecycline

Side Effects

GI disturbances , anorexia , dizziness , phlebitis , rash , headache , abscess , infections , raised ALT , AST , BUN , amylase , prolonged APTT/PT , raised INR, pruritus , inj site reactions , impaired healing , hypoglycaemia , hypoproteinaemia , increased LFTs , hepatic failure , pseudomembranous colitis and anaphylaxis .

Drug Interactions

Anticoagulants , P-gp inhibitors or inducers .

Indication

It is used in the treatment of complicated intra-abdominal infections , skin and soft tissue infections .

When not to Use

It is contraindicated for use in patients who have known hypersensitivity to tigecycline.

PRECAUTIONS

Precaution

Acute pancreatitis, including fatal cases, has occurred in association with tigecycline treatment. The diagnosis of acute pancreatitis should be considered in patients taking tigecycline who develop clinical symptoms, signs, or laboratory abnormalities suggestive of acute pancreatitis. Cases have been reported in patients without known risk factors for pancreatitis. Patients usually improve after tigecycline discontinuation. Consideration should be given to the cessation of the treatment with tigecycline in cases suspected of having developed pancreatitis .

WARNINGS

Warning 1

Anaphylactic reactions have been reported with nearly all antibacterial agents, including Tigecycline, and may be life-threatening. It is structurally similar to tetracycline-class antibacterial drugs and should be avoided in patients with known hypersensitivity to tetracycline-class antibacterial drugs.

Warning 2

Increases in total bilirubin concentration, prothrombin time and transaminases have been seen in patients treated with tigecycline. Isolated cases of significant hepatic dysfunction and hepatic failure have been reported in patients being treated with tigecycline. Some of these patients were receiving multiple concomitant medications. Patients who develop abnormal liver function tests during tigecycline therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing tigecycline therapy. Hepatic dysfunction may occur after the drug has been discontinued.

Warning 3

Hypofibrinogenemia has been reported in patients treated with Tigecycline. Obtain baseline blood coagulation parameters, including fibrinogen, and continue to monitor regularly during treatment with Tigecycline.